President Donald Trump has taken a major step in his effort to lower drug prices, signing an executive order that labels imported pharmaceutical products a threat to U.S. national security.
The order introduces sweeping tariffs on drug companies that refuse to participate in his “most-favored-nation” (MFN) pricing plan.
Tariffs as Enforcement Tool
The tariffs are issued under Section 232 of the Trade Expansion Act. This differs from the emergency-powers law the Supreme Court struck down earlier this year.
Under MFN pricing, drugmakers must charge U.S. buyers no more than the lowest price they offer in other wealthy countries.
The move marks a clear escalation. After months of voluntary agreements, the administration is now using trade policy to enforce compliance.
Companies that agree to the plan will receive a three-year exemption from tariffs. Those that refuse could face significant penalties.
TrumpRx: Ambitious but Limited
The policy ties closely to TrumpRx, a direct-to-consumer drug platform launched in February 2026.
So far, the administration says it has signed 17 MFN agreements covering about 86% of the branded drug market. The White House has described TrumpRx as “one of the most transformative health care initiatives of all time.”
But the reality is more complex.
Some companies that signed deals raised prices on other drugs earlier this year. In addition, several discounts offered through TrumpRx apply to medicines that are already available at lower prices elsewhere.
Most importantly, the platform mainly benefits:
- People who pay cash for prescriptions
- State Medicaid programs
It does not significantly help most insured Americans.
How the Deals Work
The MFN strategy began in mid-2025 when Trump asked major drugmakers to align U.S. prices with those in comparable OECD countries.
Under the agreements:
- Companies offer MFN pricing to cash-paying customers via TrumpRx
- Medicaid programs receive similar pricing
- New drugs must launch at MFN-aligned prices
In return, companies avoid tariffs.
Some price cuts have been steep:
- Pfizer reduced prices by 50% to 85%
- Ozempic dropped from about $1,000 to $350 per month
- Amgen’s Repatha fell from $573 to $239
At the same time, the administration is proposing additional programs:
- GLOBE model for Medicare Part B
- GUARD model for Medicare Part D
Both would require rebates based on international pricing. A final rule on GLOBE is expected later this year.
Who Benefits — and Who Doesn’t
TrumpRx’s structure limits its reach.
Medicaid programs benefit, but patients already pay very little out of pocket. Cash-paying individuals also gain from lower prices.
However, for the roughly 220 million Americans with private insurance, the impact is minimal.
That’s because insured patients usually pay prices already reduced by rebates and negotiations. The new deals do not require companies to lower list prices for these patients.
The platform’s drug selection also raises questions. As of April 2026, TrumpRx lists 86 drugs. Many already have cheaper generic alternatives available through services like GoodRx or Cost Plus Drugs.
Industry Concerns vs. Reform Arguments
Drugmakers argue that MFN pricing could hurt innovation.
The U.S. generates a large share of global pharmaceutical profits. That money helps fund research and development.
Lowering prices to match European levels could reduce incentives to invest in new drugs.
Large companies like Pfizer and Merck may be able to absorb the impact. Smaller biotech firms may not.
This is especially true for companies developing treatments for rare diseases such as Huntington’s disease or cystic fibrosis. These firms rely heavily on future profit expectations.
Supporters of reform disagree.
They argue that Americans already pay the highest drug prices in the world, yet still struggle with affordability. High costs lead to skipped medications and preventable hospital visits.
From this view, the issue is not innovation itself, but whether the current system is the best way to fund it.
What Happens Next
Pressure is building in Congress.
Lawmakers from both parties have asked for details on:
- The MFN agreements
- Enforcement mechanisms
- Financial impact on Medicare and Medicaid
So far, most deal terms remain confidential, raising concerns about transparency.
Early data also shows limited public engagement. Traffic to TrumpRx.gov surged at launch but quickly declined.
Meanwhile, another policy is unfolding in parallel: the Inflation Reduction Act’s Medicare drug price negotiations.
- The first 10 negotiated drugs took effect in January 2026
- The program is expected to save about $6 billion annually
- More drugs will be added in 2027 and 2028
These efforts sometimes overlap with Trump’s MFN plan, creating regulatory complexity.
A First Step, Not a Final Answer
TrumpRx is best seen as an early move, not a complete solution.
It has delivered real savings for a specific group of patients. But for most Americans, drug affordability still depends on insurance, employer benefits, and pharmacy benefit managers.
So far, those areas remain largely untouched.
Key questions remain:
- Will the GLOBE and GUARD programs move forward?
- Will tariffs force more companies to comply?
- Will reforms expand into the private insurance market?
The answers will determine whether 2026 becomes a true turning point in U.S. drug pricing — or just another step in a long and complicated process.
